Acorda's Ampyra fails main goal of post-marketing study
Mon Aug 13, 2012 7:39am EDT
(Reuters) - Acorda Therapeutics Inc said a post-marketing study of its multiple sclerosis drug Ampyra failed to meet the main trial goal of an improvement in patients' walking speed.
The 5 mg and 10 mg doses of Ampyra did not yield statistically significant results on the timed 25-foot walk test as compared with the placebo group, the company said.
http://www.reuters.com/article/2012/08/ ... FD20120813